Axil Capital's Past News
Portfolio Companies' Past News
Cranebio has been selected as COMPANY OF THE YEAR in APAC 2024 by Life Sciences Review magazine.
Luca Science gave a presentation at the 23rd Annual Meeting of the Japanese Mitochondrial Society.
Y4.com conducted a Series A round of financing.
MabGenesis conducted a capital increase through third-party allotment.
Jolly Good has launched VR service for the manufacturing industry.
GEXVal Accepted into AMED Drug Discovery Ecosystem Program.
The Japanese patent office has granted a fundamental patent related to United Immunity's PEG-free pullulan-based lipid nanoparticle.
Perseus Proteomics reported the results of the Phase 1 study of PPMX-003 at the American Society of Hematology Annual Meeting.
Elixiron Immunotherapeutics has signed the partnership agreement with National Yang Ming Chiao Tung University to promote AI drug discovery.
Hirosaki LI will take over the R&D and manufacturing business in the field of regenerative medicine of 'Foundation for Biomedical Research and Innovation at Kobe'.
The team of Cranebio and Japan Zettoc co. won a project budget from Kanagawa Prefecture for the development of a periodontal disease bacteria test kit.
United Immunity has published an academic paper on next-generation vaccines using a nanoparticle drug delivery system.
Jolly Good, in collaboration with Otsuka Pharmaceutical, has started providing VR to support dementia care.
Luca Science has published a paper in Nature Metabolism on the relief of Leigh syndrome.
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia.
Techsomed Announces U.S. Launch of BioTraceIO Vision and BioTraceIO Precision Software for Image-Guided Ablation Therapy.
Allgenesis is on track for Phase 2 clinical trial with AG-80308 for dry eye disease.
Abrax Japan aims to develop a new drug for lipid disorders.
United Immunity enters into the Research Collaboration Agreement with AstraZeneca.
Allgenesis is developing a treatment for diabetic macular edema.
HIROSAKI LI raised a total of 2.38 billion yen in a Series C round of financing.
Jolly Good partners with Persol Tempstaff to launch medical DX staffing services.
Perseus Proteomics announced the end of Ph I Clinical Trial for Polycythemia Vera.
The core technology patent for Cellusion's development products was granted in Japan.
Cranebio exhibited at the International Society of Food and Environmental Viruses.
Jolly Good partners with ExaMD, a Health and Medical AI Company.
Juran Kato, CEO of GEXVal gave a lecture at CPHI Japan 2024.
Cranebio has released a reagent kit that detects Escherichia coli by luminescence.
Otsuka Pharmaceutical and Jolly Good began offering a new Emotional Awareness Training VR program through their joint venture, FACEDUO, a virtual reality (VR) program.
A paper on corneal regenerative medicine, a joint research between Cellusion and Keio University, was published in the Keio Medical Journal.
United Immunity secures ￥180 million by Debt Financing from Aozora Corporate Investment.
Perseuse Proteomics has been adopted as Tokyo Dtrategic Innovation Promotion Program.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins.
Jolly Good Revolutionizes Healthcare with Immersive Service for Apple Vision Pro.
National Yangming Jiaotong University, a collaborative research partner of Elixiron Immunotherapeutics, published an article on fusion proteins for cancer treatment.
Techsomed's BioTrace Solution Achieves De Novo Clearance from FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation.
© Axil Capital All Rights Reserved
